image credit: Freepik

AbbVie’s IL-23 inhibitor Skyrizi approved by FDA to treat ulcerative colitis in adults

June 19, 2024


Affecting more than one million people in the US, UC is a type of inflammatory bowel disease (IBD) that causes inflammation in the digestive tract and can result in damage to the colon lining.

Patients often experience a range of unpredictable symptoms, including abdominal pain, bloody stools and an urgency to use the bathroom, and the disease can, in some cases, lead to complications such as cancer.

Skyrizi works by selectively blocking IL-23, a cytokine thought to be linked to a number of chronic immune-mediated diseases, and is already approved in the US to treat plaque psoriasis, psoriatic arthritis and Crohn’s disease.

Read More on PMLiVE